PMID- 33325013
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20211221
IS  - 1833-3516 (Print)
IS  - 2209-1491 (Electronic)
IS  - 1833-3516 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Dec 20
TI  - Effect of antiplatelet and/or anticoagulation medication on the risk of tympanic 
      barotrauma in hyperbaric oxygen treatment patients, and development of a 
      predictive model.
PG  - 338-342
LID - 10.28920/dhm50.4.338-342 [doi]
AB  - INTRODUCTION: Middle ear barotrauma (MEBt) is a common side effect of hyperbaric 
      oxygen treatment (HBOT) and can result in pain, hearing loss, tinnitus and 
      otorrhagia. The use of antiplatelet/anticoagulant drugs is thought to increase 
      the risk and severity of MEBt during HBOT. METHODS: Single centre, retrospective 
      observational cohort study of all patients treated with HBOT over a 4-year period 
      (between 01 January 2015 to 31 December 2018) looking at the incidence of MEBt 
      and the concurrent use of antiplatelet and/or anticoagulant drugs. MEBt was 
      assessed by direct otoscopy of the tympanic membrane post-HBOT and scored using 
      the modified Teed classification. Multivariate modelling assessed the 
      relationship between antiplatelet and/or anticoagulation drug use, age, sex, and 
      MEBt during HBOT. RESULTS: There was no evidence that antiplatelet and/or 
      anticoagulation drugs increase the risk of tympanic barotrauma in HBOT patients. 
      The prevalence of MEBt was higher in female patients than in males (chi2 P = 
      0.004), and increased with age (chi2 P = 0.048). No MEBt was recorded in patients 
      undergoing recompression therapy for decompression sickness or cerebral arterial 
      gas embolism. CONCLUSIONS: In this retrospective single-centre study, 
      antiplatelet and/or anticoagulation drugs did not affect the risk of MEBt, but 
      both age and sex did, with greater prevalence of MEBt among older patients and 
      females compared with younger patients and males. A predictive model, requiring 
      further validation, may be helpful in assessing the likelihood of MEBt in 
      patients undergoing HBOT.
CI  - Copyright: This article is the copyright of the authors who grant Diving and 
      Hyperbaric Medicine a non-exclusive licence to publish the article in electronic 
      and other forms.
FAU - Howard, Adam E
AU  - Howard AE
AD  - Department of Hyperbaric Medicine, Fiona Stanley Hospital, Western Australia.
AD  - Corresponding author: Dr Adam Howard, Department of Hyperbaric Medicine, Fiona 
      Stanley Hospital, 11 Robin Warren Drive, Murdoch, WA 6150, Australia, 
      adam.howard@health.wa.gov.au.
FAU - Buzzacott, Peter
AU  - Buzzacott P
AD  - Pre-Hospital, Resuscitation and Emergency Care Research Unit, School of Nursing, 
      Midwifery and Paramedicine, Curtin University, Western Australia.
FAU - Gawthrope, Ian C
AU  - Gawthrope IC
AD  - Department of Hyperbaric Medicine, Fiona Stanley Hospital, Western Australia.
AD  - University of Notre Dame, Fremantle, Western Australia.
FAU - Banham, Neil D
AU  - Banham ND
AD  - Department of Hyperbaric Medicine, Fiona Stanley Hospital, Western Australia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Australia
TA  - Diving Hyperb Med
JT  - Diving and hyperbaric medicine
JID - 101282742
RN  - 0 (Anticoagulants)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - *Barotrauma/epidemiology/etiology/therapy
MH  - Ear, Middle
MH  - Female
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Male
MH  - Oxygen
MH  - Retrospective Studies
MH  - Tympanic Membrane
PMC - PMC8026222
OTO - NOTNLM
OT  - Age
OT  - Data
OT  - Haematology
OT  - Middle ear
OT  - Risk factors
OT  - Women
COIS- Conflicts of interest and funding: nil
EDAT- 2020/12/17 06:00
MHDA- 2020/12/18 06:00
PMCR- 2021/12/20
CRDT- 2020/12/16 05:39
PHST- 2020/02/06 00:00 [received]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/12/16 05:39 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - 10.28920/dhm50.4.338-342 [doi]
PST - ppublish
SO  - Diving Hyperb Med. 2020 Dec 20;50(4):338-342. doi: 10.28920/dhm50.4.338-342.